Wall Street analysts expect Insmed, Inc. (NASDAQ:INSM) to post earnings per share (EPS) of ($0.66) for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for Insmed’s earnings, with estimates ranging from ($0.70) to ($0.59). Insmed reported earnings of ($1.10) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 40%. The company is scheduled to issue its next quarterly earnings report on Thursday, February 22nd.

On average, analysts expect that Insmed will report full year earnings of ($2.69) per share for the current year, with EPS estimates ranging from ($2.78) to ($2.59). For the next financial year, analysts forecast that the company will report earnings of ($2.46) per share, with EPS estimates ranging from ($3.60) to ($1.23). Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that cover Insmed.

A number of research firms have issued reports on INSM. BidaskClub cut Insmed from a “sell” rating to a “strong sell” rating in a report on Monday, August 14th. Cowen reiterated a “buy” rating and set a $54.00 target price on shares of Insmed in a report on Friday, November 3rd. ValuEngine upgraded Insmed from a “sell” rating to a “hold” rating in a report on Wednesday, September 6th. HC Wainwright reiterated a “buy” rating and set a $35.00 target price on shares of Insmed in a report on Wednesday, September 6th. Finally, Leerink Swann increased their target price on Insmed from $27.00 to $36.00 and gave the stock an “outperform” rating in a report on Tuesday, September 5th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company. Insmed presently has an average rating of “Hold” and an average target price of $34.50.

In other news, Director Melvin Md Sharoky sold 50,000 shares of the firm’s stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $27.37, for a total value of $1,368,500.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Donald J. Hayden, Jr. sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, November 14th. The shares were sold at an average price of $32.50, for a total value of $487,500.00. Following the completion of the transaction, the director now owns 71,131 shares of the company’s stock, valued at approximately $2,311,757.50. The disclosure for this sale can be found here. Insiders sold a total of 110,000 shares of company stock valued at $3,191,150 in the last 90 days. 5.10% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. GSA Capital Partners LLP bought a new position in shares of Insmed in the 3rd quarter valued at about $524,000. Iguana Healthcare Management LLC bought a new position in shares of Insmed in the 3rd quarter valued at about $1,561,000. Point72 Asset Management L.P. bought a new position in shares of Insmed in the 3rd quarter valued at about $3,446,000. Crestline Management LP bought a new position in shares of Insmed in the 3rd quarter valued at about $2,042,000. Finally, Janus Henderson Group PLC lifted its stake in Insmed by 140.2% in the 3rd quarter. Janus Henderson Group PLC now owns 3,960,748 shares of the biopharmaceutical company’s stock valued at $123,615,000 after purchasing an additional 2,312,045 shares during the last quarter. Institutional investors own 95.29% of the company’s stock.

Insmed (NASDAQ INSM) traded down $2.49 during mid-day trading on Monday, reaching $28.49. The company’s stock had a trading volume of 1,100,898 shares, compared to its average volume of 686,463. The company has a debt-to-equity ratio of 0.13, a current ratio of 15.21 and a quick ratio of 15.21. Insmed has a 52-week low of $11.49 and a 52-week high of $32.94.

ILLEGAL ACTIVITY NOTICE: This report was first posted by American Banking News and is owned by of American Banking News. If you are accessing this report on another website, it was stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/12/04/brokerages-expect-insmed-inc-insm-to-announce-0-66-eps.html.

About Insmed

Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC).

Get a free copy of the Zacks research report on Insmed (INSM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Insmed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.